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Introduction
Since 2006, US guidelines have recommended routine admin-
istration of human papillomavirus (HPV) vaccine to 11 or 12 y 
old females with catch-up vaccination through age 26.1 In 2011, 
guidelines expanded to recommend routine administration to 
males ages 11 or 12 with catch-up vaccination through age 21.2,3 
Despite professional recommendations and moderately high 
acceptability of HPV vaccine among parents,4,5 as of 2010, only 
49% of 13–17 y old females and just 2% of males have received 
at least one dose of HPV vaccine.6,7 The recommendation for 
routine administration to males may decrease this marked gen-
der disparity in uptake. However the continued modest uptake 
among girls, even after 6 y of recommendations for routine vac-
cination, suggests that innovative approaches to increasing use 
are warranted. This may be particularly important for older boys 
who have lower rates of preventive services use than girls.8
HPV vaccine administration in settings beyond the tradi-
tional medical home, such as schools and pharmacies, has the 
potential to effectively augment vaccine delivered in more tradi-
tional settings.9 Schools may be an effective way of reaching low-
income youth and others who may have limited access to care.10 
Low uptake of human papillomavirus (HpV) vaccine calls for innovative approaches. Offering the vaccine in settings 
outside the traditional medical home, such as schools and pharmacies, could increase use. We sought to characterize the 
acceptability of HpV vaccine delivery in these alternative settings using a national (Us) sample of parents of adolescent 
males ages 11–17 y (n = 506) and their sons (n = 391) who completed our online surveys in Fall 2010. We used multivariable 
regression to identify correlates of parents’ and sons’ comfort with (i.e., acceptability of) alternative settings. Half of 
parents (50%) and over one-third of sons (37%) reported that they were comfortable with schools or pharmacies as 
locations for the sons to receive HpV vaccine. parents and sons were more comfortable with HpV vaccination in alternative 
settings if the sons had not recently visited their health care providers or had previously received vaccines at school, 
or if parents and sons were comfortable talking with each other about new vaccines. parents who perceived greater 
barriers to HpV vaccination were more comfortable with alternative settings, as were sons who perceived that their peers 
were more accepting of HpV vaccine (all p < 0.05). Offering HpV vaccine in alternative settings may increase vaccination, 
especially among hard-to-reach adolescents. For example, our results suggest that offering the vaccine in alternative 
settings to boys who had not had recent health care visits could increase uptake by more than 10%. study findings also 
highlight factors that should be addressed to maximize the potential success of HpV vaccination programs.
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School-located vaccination has been successful in generating 
broad HPV vaccination coverage in other countries.11,12 Although 
most school-based health centers in the US offer some form of 
vaccination, including HPV vaccine,13 school-based health care is 
not widely implemented and varies by state. Pharmacies may also 
help improve HPV vaccination rates as they have for some other 
vaccines.9,14 All 50 states allow pharmacists to vaccinate adults, 
and about half allow some form of adolescent vaccination.15
Although alternative settings hold promise, little research 
has examined parent attitudes about adolescent immunizations 
in settings outside the medical home, with few of these studies 
focusing specifically on HPV vaccine.16,17 Further, little research 
on HPV vaccine delivery in alternative settings has included ado-
lescent perceptions despite evidence that adolescents are involved 
in decisions about whether to get vaccinated against HPV.18 We 
previously reported that parents and their adolescent sons most 
preferred for sons to receive HPV vaccine in a doctor’s office, 
although many were comfortable with school- and pharmacy-
located vaccination.19 However, information on correlates of 
acceptability is currently lacking, yet sorely needed, if we are to 
maximize vaccination in these alternative settings. The present 
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parents’ and sons’ comfort with sons receiving HPV vaccination 
in alternative settings.
Results
Most parents were younger than 45 y old (61%), non-Hispanic 
white (67%) and married (82%; Table 1). About half of par-
ents were female (54%) and had at least some college education 
(56%). Around one-third each of participating sons were ages 
11–12 (30%), 13–15 (38%) and 16–17 (32%), and 21% of sons 
had not seen a health care provider for a preventive visit in the 
previous year.
Sons perceived moderate levels of peer acceptance of HPV 
vaccine (mean = 3.03, SD = 0.60) but also moderate levels of 
potential embarrassment if they got vaccinated against HPV and 
their friends found out (mean = 3.00, SD = 1.00). In general, 
parents and sons had moderate to high levels of comfort talking 
with each other about new vaccines (parents: mean = 4.35, SD = 
0.79; sons: mean = 3.60, SD = 1.06), and about 1 out of 6 sons 
(14%) had previously received vaccines at school.
Half of parents (50%, 254/506) and over one-third of sons 
(37%, 143/391) reported that they were comfortable or very 
comfortable with either school or pharmacy-located HPV vacci-
nation. Both parents and sons were moderately comfortable with 
sons receiving HPV vaccine in alternative settings (parents: mean 
= 2.89, SD = 1.14; sons: mean = 2.59, SD = 1.08). Sons’ comfort 
was positively correlated with their parents’ comfort (r = 0.50, p 
< 0.001), though parents were on average slightly more comfort-
able with alternative settings than sons (mean difference = 0.30, 
t(390) = 5.34, p < 0.001).
Correlates of parents’ comfort. In multivariable analyses, 
parents were more comfortable with vaccination in alternative 
settings if they lived in the southern region of the US (compared 
with the western region, β = 0.13), if their sons had not seen a 
health care provider in the past year (β = 0.09), or if their sons 
had previously received vaccines at school (β = 0.17; Table 2). 
Parents were also more comfortable with alternative vaccination 
settings if they reported greater comfort talking with their sons 
about new vaccines (β = 0.08) or perceived greater barriers to get-
ting their sons vaccinated against HPV (β = 0.10). Parents were 
less comfortable with their sons receiving HPV vaccination in 
alternative settings if they had higher levels of either uncertainty 
about HPV vaccine (β = -0.17) or anticipated regret if their sons 
got vaccinated and fainted (β = -0.16).
Correlates of sons’ comfort. In multivariable analyses, sons 
were more comfortable with vaccination in alternative settings if 
they were Hispanic (as compared with non-Hispanic white; β = 
0.14), lived in an urban area (β = 0.17), or had not seen a health 
care provider in the past year (β = 0.11; Table 3). Compared 
with sons who had never received vaccines at school, sons who 
had either previously received vaccines at school or didn’t know 
if they had were more comfortable with alternative vaccination 
setting (β = 0.13 and β = 0.12, respectively). Sons were also more 
comfortable with alternative vaccination settings if they were 
more comfortable talking with their parents about new vaccines 
(β = 0.13) or perceived that their peers were more accepting of 








< 45 y 309 (61.1)
≥ 45 y 197 (38.9)
Race / ethnicity
Non-Hispanic White 340 (67.2)
Non-Hispanic Black 62 (12.3)
Hispanic 78 (15.4)
Other race/ethnicity 26 (5.1)
education
High school degree or less 223 (44.1)
some college or more 283 (55.9)
Marital status
Divorced, widowed, separated, never married 91 (18.0)
Married or living with a partner 415 (82.0)
Son Characteristicsa
age
11–12 y 119 (30.4)
13–15 y 149 (38.1)
16–17 y 123 (31.5)
Race / ethnicity
Non-Hispanic White 240 (61.4)
Non-Hispanic Black 48 (12.3)
Hispanic 63 (16.1)
Other race/ethnicity 40 (10.2)





< $60,000 253 (50.0)









aData collected during parent survey, but we report data only for those 
sons who completed their own surveys. sons who completed surveys 
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Table 2. parents’ comfort with getting their sons HpV vaccine in alternative settings (n = 506)
Comfort Bivariate Multivariable
Mean (SD) β (95% CI) β (95% CI)
Parent characteristics
sex
Female 2.93 (1.18) ref -
Male 2.85 (1.09) -0.03 (-0.12, 0.15) -
age
< 45 y 2.91 (1.18) ref -
≥ 45 y 2.86 (1.11) -0.02 (-0.11, 0.07) -
Race/ethnicity
Non-Hispanic White 2.87 (1.17) ref -
Non-Hispanic Black 2.96 (0.98) 0.03 (-0.06, 0.12) -
Hispanic 2.87 (1.10) 0.00 (-0.09, 0.09) -
Other race/ethnicity 3.10 (1.20) 0.04 (-0.04, 0.13) -
education
High school degree or less 2.95 (1.16) ref -
some college or more 2.85 (1.12) -0.04 (-0.13, 0.04) -
Marital status
Divorced, widowed, separated, never married 2.89 (1.08) ref -
Married or living with a partner 2.89 (1.15) 0.00 (-0.09, 0.09) -
Son characteristics
age
11–12 y 2.73 (1.15) ref ref
13–15 y 2.91 (1.17) 0.08 (-0.03, 0.22) 0.02 (-0.07, 0.12)
16–17 y 3.02 (1.08) 0.12 (0.02, 0.23)* 0.05 (-0.05, 0.15)
saw a health care provider in past year
No 3.10 (1.09) 0.09 (0.01–0.18)* 0.09 (0.01, 0.18)*
Yes 2.84 (1.14) ref ref
ever received any vaccines at school
No 2.79 (1.12) ref ref
Yes 3.45 (1.09) 0.20 (0.11, 0.29)** 0.17 (0.09, 0.26)**
Don’t know 3.00 (1.16) 0.03 (-0.06, 0.12) 0.01 (-0.08, 0.09)
Household characteristics
annual household income
< $60,000 2.98 (1.14) ref -
≥ $60,000 2.81 (1.13) -0.07 (-0.16, 0.1) -
Urbanicity
Rural 2.96 (1.10) ref -
Urban 2.88 (1.15) -0.03 (-0.12, 0.06) -
Region of residence
West 2.64 (1.14) ref ref
Midwest 2.98 (1.12) 0.12 (0.01, 0.24)* 0.09 (-0.01, 0.20)
Note: Table presents standardized regression coefficients (β) from linear regression models. Dashes (–) indicate that the model did not include the 
item. HpV, human papillomavirus; sD, standard deviation; ref, referent category. aNo (38%), Yes (14%), Did not have a daughter (48%); bNo (10%), Yes 
(21%), Don’t know (69%); cNo (98%), Yes (2%); dcontinuous variable with overall mean (sD) reported. e4-point response scale ranging from “not at all” 
to “a lot” (coded 1–4). f4-point response scale ranging from “no chance” to “high chance” (coded 1–4). g2 item scale; each item had a 5-point response 
scale ranging from “very uncomfortable” to “very comfortable” (coded 1–5). h3 item scale; each item had a 5-point response scale ranging from 
“strongly disagree” to “strongly agree” (coded 1–5). fi5 item scale; each item had a 5-point response scale ranging from “strongly disagree” to “strongly 
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settings. Consistent with previous research,21 these findings sug-
gest that offering HPV vaccination in alternative settings may 
be a way to reach young people at most risk of not getting the 
vaccine through more traditional venues. This could result in a 
substantial increase in HPV vaccine uptake. For example, while 
we found that about 1 in 5 sons had not had a recent visit with 
a health care provider, in over half of these cases, parents were 
comfortable with adolescent vaccination in an alternative setting. 
This suggests that even by reaching only these sons, offering the 
vaccine in alternative settings could translate into an additional 
12% of all sons in this sample getting vaccinated against HPV.
While previous research has examined potential benefits and 
concerns about alternative settings for adolescent vaccination 
descriptively, to our knowledge, the present study is among the 
first to identify modifiable correlates that can guide efforts to 
promote HPV vaccination in alternative settings. For example, 
parents’ and sons’ comfort communicating with each other about 
new vaccines was a significant and novel correlate of comfort 
with HPV vaccination in alterative settings which, to our knowl-
edge, has not been reported in the literature on general HPV 
HPV vaccine (β = 0.18). Sons were less comfortable with receiv-
ing HPV vaccine in alternative settings if they had higher lev-
els of potential embarrassment if they got vaccinated and their 
friends found out (β = -0.20) or anticipated regret if they got 
vaccinated and fainted (β = -0.19).
Discussion
Recognizing that current systems of care are not meeting the 
complex needs of adolescents, the Institute of Medicine issued 
a report in 2009 calling for the development of innovative pro-
grams to improve health and health care, particularly for young 
people who are most vulnerable to poor health outcomes.20 
Similarly, low uptake of HPV vaccine and significant disparities 
in vaccination rates7 point to the need for innovative approaches 
to increasing use. In this national sample, parents who per-
ceived greater barriers to vaccination, as well as both parents and 
sons who reported that the son did not have recent health care 
visit, had greater comfort with HPV vaccination in alternative 
Table 2. parents’ comfort with getting their sons HpV vaccine in alternative settings (n = 506)
Northeast 2.88 (1.13) 0.07 (-0.04, 0.18) 0.06 (-0.04, 0.16)
south 3.02 (1.14) 0.15 (0.04, 0.27)* 0.13 (0.02, 0.24)*
HPV and HPV vaccine
Daughter has received HpV Vaccinea
No 2.83 (1.16) ref ref
Yes 3.15 (1.13) 0.10 (0.01, 0.19)* 0.01 (-0.09, 0.10)
Does not have a daughter 2.87 (1.12) 0.02 (-0.08, 0.11) -0.01 (-0.10, 0.08)
Thinks son’s insurance covers HpV vaccineb
No 3.03 (1.15) ref -
Yes 2.81 (1.14) -0.08 (-0.21, 0.06) -
Don’t know 2.89 (1.14) -0.05 (-0.19, 0.08) -
son’s doctor said son should get HpV vaccinec
No 2.90 (1.14) ref -
Yes 2.71 (0.96) -0.03 (-0.11, 0.06) -
Worry about son getting HpV-related diseased,e 1.45 (0.76) 0.10 (0.02, 0.19)* 0.01 (-0.08, 0.10)
perceived likelihood of son getting HpV-related diseased,f 2.20 (0.63) 0.14 (0.06, 0.23)** 0.06 (-0.03, 0.15)
comfort talking with son about new vaccinesd,g 4.35 (0.79) 0.12 (0.04, 0.21)* 0.08 (0.01, 0.16)*
amount talked with son about HpV vaccined,e 1.18 (0.49) 0.08 (-0.01, 0.17) -
perceived effectiveness of HpV vaccined,e 2.41 (0.92) 0.18 (0.09–0.26)** 0.02 (-0.07, 0.11)
perceived uncertainty of HpV vaccined,h 3.57 (0.67) -0.23 (-0.31, -0.14)** -0.17 (-0.26, -0.09)**
perceived harms of HpV vaccined,i 3.03 (0.53) -0.23 (-0.31, -0.14)** -0.08 (-0.18, 0.01)
perceived barriers to getting son HpV vaccined,j 1.36 (0.47) 0.09 (0.01, 0.18)* 0.10 (0.02, 0.18)*
anticipated regret if son got HpV vaccine and faintedd,e 2.70 (1.07) -0.25 (-0.33, -0.16)** -0.16 (-0.25, -0.07)**
anticipated regret if son didn’t get HpV vaccine and later got HpV infectiond,e 3.17 (0.94) 0.10 (0.02, 0.19)* 0.03 (-0.06, 0.12)
Note: Table presents standardized regression coefficients (β) from linear regression models. Dashes (–) indicate that the model did not include the 
item. HpV, human papillomavirus; sD, standard deviation; ref, referent category. aNo (38%), Yes (14%), Did not have a daughter (48%); bNo (10%), Yes 
(21%), Don’t know (69%); cNo (98%), Yes (2%); dcontinuous variable with overall mean (sD) reported. e4-point response scale ranging from “not at all” 
to “a lot” (coded 1–4). f4-point response scale ranging from “no chance” to “high chance” (coded 1–4). g2 item scale; each item had a 5-point response 
scale ranging from “very uncomfortable” to “very comfortable” (coded 1–5). h3 item scale; each item had a 5-point response scale ranging from 
“strongly disagree” to “strongly agree” (coded 1–5). fi5 item scale; each item had a 5-point response scale ranging from “strongly disagree” to “strongly 
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Table 3. sons’ comfort getting HpV vaccine in alternative settings (n = 391)
Comfort Bivariate Multivariable
Mean (SD) β (95% CI) β (95% CI)
Son characteristics
agea
11–12 y 2.39 (1.15) ref ref
13–15 y 2.61 (1.00) 0.10 (-0.02, 0.22) 0.07 (-0.03, 0.17)
16–17 y 2.76 (1.09) 0.16 (0.04, 0.28)* 0.07 (-0.03, 0.18)
Race / ethnicitya
Non-Hispanic White 2.48 (1.07) ref ref
Non-Hispanic Black 2.66 (1.03) 0.05 (-0.05, 0.16) 0.08 (-0.01, 0.16)
Hispanic 2.96 (1.17) 0.16 (0.06, 0.27)* 0.14 (0.05, 0.23)*
Other race/ethnicity 2.63 (1.01) 0.04 (-0.06, 0.14) 0.05 (-0.03, 0.15)
saw a health care provider in past yeara
No 2.86 (1.05) 0.13 (0.03, 0.23)* 0.11 (0.02, 0.19)*
Yes 2.52 (1.08) ref ref
ever received any vaccines at schoola
No 2.51 (1.05) ref ref
Yes 2.90 (1.20) 0.12 (0.03, 0.22)* 0.13 (0.05, 0.22)*
Don’t know 3.55 (0.72) 0.15 (0.05, 0.25)** 0.12 (0.03, 0.20)*
Household characteristics
annual household income
< $60,000 2.26 (1.03) ref –
≥ $60,000 2.66 (1.08) 0.01 (-0.08, 0.11) –
Urbanicity
Rural 2.26 (1.03) ref ref
Urban 2.66 (1.08) 0.14 (0.04, 0.24)* 0.17 (0.08, 0.26)**
Region of residence
West 2.51 (1.1) ref –
Midwest 2.44 (1.00) -0.03 (-0.15, 0.10) –
Northeast 2.67 (1.10) 0.06 (-0.07, 0.18) –
south 2.70 (1.11) 0.08 (-0.05, 0.21)
HPV and HPV vaccine
HpV knowledgeb
Never heard of HpV prior to survey 2.54 (1.07) ref –
Heard of HpV, low knowledge 2.75 (1.00) 0.06 (-0.04, 0.16) –
Heard of HpV, high knowledge 2.75 (1.17) 0.07 (-0.03, 0.17) –
sister had received HpV vaccinea
No 2.58 (1.09) ref –
Yes 2.86 (1.03) 0.09 (-0.02, 0.20) –
Did not have a sister 2.53 (1.09) -0.02 (-0.13, 0.08) –
perceived likelihood of getting HpV-related diseasec,d 2.04 (0.67) 0.12 (-0.02, 0.22)* -0.02 (-0.11, 0.07)
Note: Table presents standardized regression coefficients (β) from linear regression models. Dashes (–) indicate that the model did not include the 
item. HpV, human papillomavirus; sD, standard deviation; ref, referent category. aData collected during parent survey. bMost sons (75%) had never 
heard of HpV prior to the survey. among those who were aware of HpV, 9% had low knowledge and 16% had high knowledge about the virus. ccontin-
uous variable with overall mean (sD) reported. d4-point response scale ranging from “no chance” to “high chance” (coded 1–4). e2 item scale; each item 
had a 5-point response scale ranging from “very uncomfortable” to “very comfortable” (coded 1–5). f4-point response scale ranging from “not at all” to 
“a lot” (coded 1–4). g4 item scale; each item had a 5-point response scale ranging from “strongly disagree” to “strongly agree” (coded 1–5). h2 item scale; 
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pattern—students with the greatest exposure to school-based 
health care have the most favorable attitudes, and students who 
utilize services express high levels of satisfaction.25 Further, in 
other research, 40% of parents consenting to school-located vac-
cination for their children had previously indicated that schools 
were not a preferred setting, suggesting that hypothetical prefer-
ences may not reflect actual use when given the opportunity to 
vaccinate in an alternative setting.26
Although the coefficients we report for some correlates may 
be relatively small, if addressed at a population level,27 the fac-
tors identified in this study could increase acceptability of HPV 
vaccine delivery in alternative settings and, potentially, vaccine 
uptake. However, previous research also identifies other salient 
factors for utilization of these settings. Efforts to maximize HPV 
vaccine delivery in alternative settings will also need to address 
multiple policy and logistical concerns that are beyond the scope 
of the current study, such as coordinating medical/vaccination 
records with the medical home, billing insurance and obtaining 
parental consent where necessary.13,14,16,19,21,28 Additional research 
is needed to identify strategies to increase acceptability, evalu-
ate the feasibility of wide-scale implementation of vaccination 
located in alternative settings, and explore ways to ensure conti-
nuity of care with the medical home.
Study strengths include the use of a population-based sample 
and the inclusion of novel survey items about alternative vaccina-
tion settings. Our study is further strengthened by the inclusion 
of adolescent perspectives which can help to ensure the relevance 
of interventions to this population. However, our study also has 
several limitations. At the time we conducted the survey, many 
parents and sons were unaware that HPV vaccine could be given 
to males;6 while the survey provided information about HPV 
vaccine for males to all participants, responses may nonethe-
less reflect a lack of knowledge and familiarity with the vaccine 
itself. Further, survey questions were about a hypothetical situ-
ation (i.e., one that posited they had decided for sons to receive 
the vaccine), which may not reflect actual comfort or utilization 
when faced with actual opportunities. Comfort levels measured 
in advance of the widespread promotion of HPV vaccination in 
alternative settings may not accurately reflect ultimate utilization. 
Although the online panel is comparable to the US population on 
many sociodemographic characteristics,29 most participants were 
vaccine acceptability. It may be that communication is particu-
larly important for vaccination in settings where the parent may 
not be present (such as school), as wanting parents to be present 
during vaccination has been reported as a concern about vaccine 
delivery in alternative settings.19,21 Promoting parent-child com-
munication about health care and vaccination could help allay 
some concerns, though research is needed on the best way to do 
so.
Consistent with previous research on general HPV vaccine 
acceptability among both males6 and females,22 we found that 
sons’ perceived peer acceptance of HPV vaccination is an impor-
tant correlate of comfort with vaccination in alternative settings. 
We also found that sons’ potential embarrassment from getting 
vaccinated could be a barrier that may be heightened in alterna-
tive settings. Efforts to normalize HPV vaccination among ado-
lescents and provide assurances of privacy and confidentiality in 
alternative settings may help increase comfort among sons.
In contrast to our previous research showing that anticipated 
regret of not vaccinating and later getting an HPV-related infec-
tion was an important longitudinal predictor of HPV vaccine 
uptake among parents of adolescent girls,23 inaction regret was 
not a correlate of comfort in this study. Instead, we found that 
anticipated action regret (i.e., anticipated regret if sons received 
the vaccine and fainted) was a strong and consistent correlate of 
comfort with alternative settings for both groups. This type of 
anticipated regret may be more salient when considering the con-
crete consequences of vaccine receipt in situations where parents 
may not be present for vaccination or sons might feel embarrassed 
or concerned that other people might find out.19,21 In addition to 
educating parents and sons about the level of provider training 
and privacy of vaccination settings, providers may be able further 
able to address concerns about fainting and other adverse events, 
as data from females’ vaccination experiences suggest that these 
events are relatively rare and no greater for HPV vaccine than 
other adolescent vaccines.24
We found that previous experience with school-located vac-
cination was a consistent correlate of comfort with HPV vac-
cination in alternative settings for both parents and sons. This 
may reflect greater exposure to, or even positive experiences 
with, health care venues outside of the medical home. Research 
on attitudes toward school-based health centers shows a similar 
Table 3. sons’ comfort getting HpV vaccine in alternative settings (n = 391)
comfort talking with parents about new vaccinesc,e 3.60 (1.06) 0.22 (0.12, 0.32)** 0.13 (0.04, 0.22)*
amount talked with parents about HpV vaccinec,f 1.12 (0.42) 0.01 (-0.09, 0.11) –
perceived peer acceptance of HpV vaccinec,g 3.03 (0.60) 0.32 (0.23, 0.41)** 0.18 (0.08, 0.27)**
potential embarrassment of getting HpV vaccinec,h 3.00 (1.06) -0.34 (-0.43, -0.25)** -0.20 (-0.29, -0.11)**
anticipated regret if got HpV vaccine and faintedc,f 2.79 (1.11) -0.30 (-0.39, -0.20)** -0.19 (-0.28, -0.10)**
anticipated regret if didn’t get HpV vaccine and later got HpV infectionc,f 3.13 (1.00) 0.07 (-0.03, 0.17) –
Note: Table presents standardized regression coefficients (β) from linear regression models. Dashes (–) indicate that the model did not include the 
item. HpV, human papillomavirus; sD, standard deviation; ref, referent category. aData collected during parent survey. bMost sons (75%) had never 
heard of HpV prior to the survey. among those who were aware of HpV, 9% had low knowledge and 16% had high knowledge about the virus. ccontin-
uous variable with overall mean (sD) reported. d4-point response scale ranging from “no chance” to “high chance” (coded 1–4). e2 item scale; each item 
had a 5-point response scale ranging from “very uncomfortable” to “very comfortable” (coded 1–5). f4-point response scale ranging from “not at all” to 
“a lot” (coded 1–4). g4 item scale; each item had a 5-point response scale ranging from “strongly disagree” to “strongly agree” (coded 1–5). h2 item scale; 
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vaccine…” Questions asked participants how comfortable they 
were with the sons getting HPV vaccine at: (1) a local pharmacy 
or drug store if they offered the vaccine, and (2) the son’s school 
if they offered the vaccine in a nurse’s office. Both items had a 
5-point response scale ranging from “very uncomfortable” to 
“very comfortable” (coded 1–5 with higher values indicating 
greater comfort). To clarify the meaning of “comfortable,” sur-
veys indicated that the items were not about whether the shots 
themselves would be painful. We created a composite measure 
of comfort with alternative site vaccination based on the mean 
of the two items (possible range: 1–5). Analyses use a composite 
that is the average of the two items, as they were highly correlated 
(r = 0.49 and 0.47 for parent and son surveys, respectively), had 
similar means (p > 0.05 for both groups) and showed similar pat-
terns of correlates.
The survey assessed parents’ and sons’ HPV knowledge, HPV 
vaccine attitudes and beliefs,30 and previous experience with vac-
cination in alternative settings.6 We also collected information 
on various sociodemographic characteristics (age, race/ethnicity, 
income, urbanicity and region of residence), defining “urban” as 
living in a metropolitan statistical area (MSA) and “rural” as liv-
ing outside of an MSA.31
Data analysis. We calculated Pearson’s correlation coefficient 
to determine the correlation between parents’ and sons’ comfort 
and used a paired t-test to assess the mean difference in their 
comfort with alternative settings. We used linear regression 
to identify bivariate correlates of parent and son comfort with 
receiving HPV vaccine in alternative vaccine delivery settings. 
Multivariable regression models included all variables associated 
(p < 0.05) in bivariate analyses. We report data from parent and 
son surveys separately as standardized regression coefficients (βs). 
We conducted all analyses in Stata SE version 10.0 (Statacorp) 
using two-tailed tests and a critical α of 0.05.
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non-Hispanic white and of fairly high socioeconomic status. Our 
study focused on vaccination of adolescent males; generalizabil-
ity to other populations, including adolescent girls, needs to be 
established.
Taken together with other research on acceptability of deliv-
ering adolescent vaccines outside the medical home,16,17,21,28 the 
moderate levels of comfort among parents and sons in our study 
are promising for expanding vaccine coverage in the US and 
hopefully increasing coverage rates to match those of other coun-
tries (e.g., Australia and the UK) that already offer the vaccine 
non-traditional settings. Indeed, comfort with these settings may 
be higher as such programs become more common.
Materials and Methods
This study uses data from the HPV Immunization in Sons 
(HIS) study which examined HPV vaccine attitudes and beliefs 
of parents and their adolescent sons.6 During August and 
September 2010, we surveyed a national sample of parents of 
adolescent males ages 11–17. All parents were members of an 
existing national panel of US households that a survey company 
created using a dual frame approach combining list-assisted, 
random-digit dialing and address-based random sampling of US 
households.29 In exchange for completing surveys, panel mem-
bers accumulated points that they could redeem for small cash 
payments. Households without pre-existing internet received 
a laptop computer and internet access. We asked participating 
parents to also allow their sons to participate. The Institutional 
Review Board at the University of North Carolina approved the 
study.
The survey company invited 1,195 parents to complete our 
online survey, and 752 responded. Of those, 547 (73%) parents 
were eligible to participate, consented and completed the par-
ent survey. Over half of responding parents (56%, n = 421) had 
sons who assented and participated by taking the son survey. For 
the present analysis, we excluded participants when the sons had 
received at least one dose of HPV vaccine (parent survey, n = 12; 
son survey, n = 9) or who were home schooled (parents, n = 29; 
sons, n = 21), resulting in an analytic sample size of 506 parents 
and 391 sons.
Measures. The parent and son surveys (available online at: 
www.unc.edu/~ntbrewer/hpv.htm) included established mea-
sures in the literature as well as our own previous research with 
parents of adolescent daughters.16,23,30 Prior to survey admin-
istration, we cognitively tested the survey with 6 parent-son 
dyads to ensure that survey instructions and items were clear 
and confirm that participants interpreted items as intended.
We provided all participants with information about HPV 
and HPV vaccine throughout the survey. Parent and son surveys 
included equivalent items about vaccine delivery in alternative 
settings. To focus on acceptability of delivery settings, rather 
than the vaccine itself, each question began with the stem: “If 
you and [son’s name (parent survey)/your parents (son survey)] 
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